Nabriva Therapeutics Plc
US ˙ NASDAQ ˙ IE00BL53QQ85
DETTE SYMBOL ER IKKE LÆNGERE AKTIVT

SecurityNBRV / Nabriva Therapeutics Plc
InstitutionFT Options LLC
Latest Disclosed Ownership20,000 shares
Latest Disclosed Value $ 164,000
FT Options LLC reports 32.28% increase in ownership of NBRV / Nabriva Therapeutics Plc

On November 13, 2017 - FT Options LLC filed a 13F-HR form disclosing ownership of 20,000 shares of Nabriva Therapeutics Plc (US:NBRV) valued at $40,950,000 USD as of September 30, 2017. The entity filed a previous 13F-HR on August 11, 2017 disclosing 15,120 shares of Nabriva Therapeutics Plc. This represents a change in shares of 32.28% during the quarter. The current value of the position is $28,400 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2017-11-13 2017-09-30 13F NABRIVA THERAPEUTICS SHS G63637105 20,000 4,880 32.28 164 -3.53 0.2471
2017-08-11 2017-06-30 13F NABRIVA THERAPEUTICS SHS G63637105 15,120 -4,728 -23.82 170 -28.57 0.2928
2017-05-12 2017-03-31 13F NABRIVA THERAPEUTICS SPONSORED ADR 62957M104 19,848 -63,207 -76.10 238 -51.82 0.3133
2017-02-10 2016-12-31 13F NABRIVA THERAPEUTICS SPONSORED ADR 62957M104 83,055 25,000 43.06 494 19.32 0.5673
2016-11-10 2016-09-30 13F NABRIVA THERAPEUTICS SPONSORED ADR 62957M104 58,055 8,500 17.15 414 11.29 0.3282
2016-08-12 2016-06-30 13F NABRIVA THERAPEUTICS SPONSORED ADR 62957M104 49,555 26,392 113.94 372 78.85 0.3195
2016-05-09 2016-03-31 13F NABRIVA THERAPEUTICS SPONSORED ADR 62957M104 23,163 23,163 0.00 208 0.2179
2016-02-05 2015-12-31 13F NABRIVA THERAPEUTICS SPONSORED ADR 62957M104 0 0
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.